1056 XTX301, a tumor activated, half-life extended IL-12 promoted potent anti-tumor immunity and activity across multiple syngeneic tumor models

• Wilson Guzman,
• Damiano Fantini,
• Parker Johnson,
• Kurt Jenkins,
• Hanumantha Rao Madala,
• Caitlin O’Toole,
• Magali Pederzoli-Ribeil,
• Jennifer O’Neil,
• Jake Taylor,
• Ekta Patel,
• Sallyann Vu,
• Manoussa Fanny,
• Oleg Yerov,
• Benjamin Nicholson,
• Natalia V Malkova,
• Stephanie Hsiao,
• Ertan Eryilmaz,
• Uli Bialucha

Affiliations

Wilson Guzman

Aff1 ImmunoOncology, EMD Serono Research & Development Institute Inc. Billerica MA USA

Damiano Fantini

Eli Lilly and Company, Indianapolis, Indiana, USA

Parker Johnson

Xilio Therapeutics, Waltham, MA, USA

Kurt Jenkins

Xilio Therapeutics, Waltham, MA, United States

Hanumantha Rao Madala

Xilio Therapeutics, Waltham, MA, USA

Caitlin O’Toole

Xilio Therapeutics, Waltham, MA, USA

Magali Pederzoli-Ribeil

2CNRS UMR 8104, Paris, France

Jennifer O’Neil

Xilio Therapeutics, Waltham, MA, USA

Jake Taylor

3 Medical School, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UK

Ekta Patel

Obstetrics and Gynaecology, East and North Hertfordshire NHS Trust, Stevenage, Hertfordshire, UK

Sallyann Vu

Xilio Therapeutics, Waltham, MA, United States

Manoussa Fanny

Xilio Therapeutics, Waltham, MA, United States

Oleg Yerov

Xilio Therapeutics, Waltham, MA, United States

Benjamin Nicholson

Xilio Therapeutics, Waltham, MA, United States

Natalia V Malkova

Xilio Therapeutics, Allston, MA, USA

Stephanie Hsiao

Xilio Therapeutics, Allston, MA, USA

Ertan Eryilmaz

Xilio Therapeutics, Allston, MA, USA

Uli Bialucha

Xilio Therapeutics, Allston, MA, USA